With Exopol from Spain and INVAC from Germany Klaus-Peter Behr, Chairman, could welcome two new members at the 8th ordinary General Assembly on 19th of April.
Exopol, represented at the meeting in Paris by Ana Fernández and Silvia Ania, is a Spanish private company with business activities in diagnostic services, diagnostic qPCR kits and autogenous vaccine. Exopol offers autogenous vaccines for different animal species, like swine, ruminants, rabbits and poultry.
INVAC is a new-born German based company with a focus on veterinary diagnostics, the production of autogenous vaccines, feed and food analytics and in research and development. INVAC, represented by Martin Metzner and Alexander Repp, has a competence in manufacturing and consultancy of use of autogenous vaccines in Livestock (poultry, swine, cattle, goat, sheep, fish) as well as in Pets and Zoo animals.
In the annual report of the executive Board Klaus-Peter Behr stated that 2022 was a challenging like successful year for EMAV: Important EMAV projects could be finalized, key positions of EMAV for a new GMP guidance for autogenous vaccines were placed on the right track and EMAV’s competence as representative of the manufacturers of autogenous vaccines in Europe was strengthened. Therefore the last year was a very productive and significant one for the association again.
Following the EMAV statutes members took the opportunity to elect a new EMAV Board. As Chairman Dr. Klaus-Peter Behr and Maarten de Gussem (Poulpharm/BE) were re-elected. Maarten will act as Deputy Chair in addition too. The Board was completed by Thierry Le Flohic (CEVA-Biovac/FR) and Dr. Hans-Christian Philipp (Vaxxinova/DE) as new members. Gerfried Zeller, Managing Director of EMAV, shows pleasure about the election of such a competent and trusted EMAV leadership team in a challenging phase of the implementation of Reg. (EC) 2019/6 for a detailed guidance in manufacturing and use of autogenous vaccines in Europe in future.